• Quanterix posted a press release noting Anthem Blue Cross and Blue Shield commercial coverage for LucentAD Complete blood-based Alzheimer’s testing from July 1, 2026.
• Coverage applies when medical-necessity criteria are met under LAB.00046: Testing for Biochemical Markers for Alzheimer Disease.
• Release also cited a peer-reviewed study reporting diagnostic parity versus an IP-MS method; multi-analyte algorithm cut indeterminate results about three-fold.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quanterix Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260714466817) on July 14, 2026, and is solely responsible for the information contained therein.